A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
-
Singapore, Singapore, 138623
- Not yet recruiting
- Lilly Centre for Clinical Pharmacology
-
Contact:
- Phone Number: 64139811
-
Principal Investigator:
- Jennifer Boon Wee
-
-
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Not yet recruiting
- Woodland Research Northwest, LLC
-
Contact:
- Phone Number: 479-927-3000
-
Principal Investigator:
- Timothy Cook
-
-
California
-
Anaheim, California, United States, 92801
- Recruiting
- CenExel ACT
-
Principal Investigator:
- Amina Haggag
-
Los Alamitos, California, United States, 90720
- Recruiting
- Collaborative Neuroscience Network - CNS
-
Principal Investigator:
- Steven Reynolds
-
Walnut Creek, California, United States, 94598
- Recruiting
- Diablo Clinical Research, Inc.
-
Principal Investigator:
- Bonnie Kimmel
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
- Recruiting
- Fortrea Clinical Research Unit
-
Contact:
- Phone Number: 866-429-3700
-
Principal Investigator:
- Chiamaka Iheme
-
Miami, Florida, United States, 33417
- Not yet recruiting
- Advanced Pharma CR, LLC
-
Principal Investigator:
- Simon Abelson
-
Winter Park, Florida, United States, 32789
- Recruiting
- Clinical Site Partners, LLC DBA CSP Orlando
-
Principal Investigator:
- ROBERT MEYER
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Recruiting
- Centricity Research
-
Principal Investigator:
- Joseph Surber
-
Contact:
- Phone Number: 706-321-0495
-
Decatur, Georgia, United States, 30030
- Recruiting
- CenExel iResearch, LLC
-
Principal Investigator:
- Kimball Johnson
-
-
Missouri
-
Springfield, Missouri, United States, 65802
- Recruiting
- QPS
-
Principal Investigator:
- Leea Reed
-
Contact:
- Phone Number: 417-893-6161
-
-
New Jersey
-
Marlton, New Jersey, United States, 08053
- Recruiting
- CenExel-HRI
-
Principal Investigator:
- Kyle Coupe
-
-
Ohio
-
Columbus, Ohio, United States, 43212
- Recruiting
- Ohio Clinical Trials
-
Principal Investigator:
- Angela Eakin
-
-
Texas
-
Dallas, Texas, United States, 75247
- Recruiting
- Fortrea Clinical Research Unit
-
Principal Investigator:
- Archie Bowie
-
San Antonio, Texas, United States, 78217
- Recruiting
- Worldwide Clinical Trials, Inc.
-
Principal Investigator:
- Alan Hand
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be 21 in Singapore.
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
-
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- prediabetes.
Part C
- Have a BMI ≥25.0 kg/m²
- Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
- T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
- Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
- To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
- To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
- Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: LY4167586
LY4167586 administered subcutaneously (SC) |
administered SC |
|
Experimental: Part B LY4167586
LY4167586 administered SC |
administered SC |
|
Experimental: Part C LY4167586
LY4167586 administered SC |
administered SC |
|
Experimental: Part D LY4167586
LY4167586 administered SC |
administered SC |
|
Experimental: Part E LY4167586
LY4167586 administered SC |
administered SC |
|
Placebo Comparator: Placebo (Part A-E)
Placebo administered SC |
administered SC |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline through Study Completion (Estimated as Week 89)
|
Baseline through Study Completion (Estimated as Week 89)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
Time Frame: Baseline up to Week 89
|
Baseline up to Week 89
|
|
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
Time Frame: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Body Weight Observed Value
Time Frame: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Change from Baseline in Body Weight
Time Frame: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Percent Change from Baseline in Body Weight
Time Frame: Baseline up to Week 89
|
Baseline up to Week 89
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 27671
- J6L-MC-YIAB (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.